Lirodegimod

N/A

Report date: 2025/03/12 10:27:34
NME

Base Information

Drug NameLirodegimod
Drug Alias NameKT-333I-003
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionSignal transducer and activator of transcription 3 degraders
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsSolid tumoursLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A